Pitfalls in blood pressure measurement in daily practice

Family Practice

Volumn 23, Issue 1, 2006, Pages 20-27

  Houweling, Sebastiaan T ^a,b   Kleefstra, N ^a   Lutgers, H L ^a,b   Groenier, K H ^b   Meyboom de Jong, B ^b   Bilo, H J G ^a  

^a ISALA HOSPITAL   (Netherlands)

^b UNIVERSITY OF GRONINGEN   (Netherlands)

Author keywords

Blood pressure determination; Clinical trials; Human; Hypertension; Practice guidelines

Indexed keywords

ADULT; AGED; ANALYSIS OF VARIANCE; ARTICLE; BLOOD PRESSURE MEASUREMENT; CLINICAL PROTOCOL; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIASTOLIC BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OUTCOMES RESEARCH; PRACTICE GUIDELINE; PROFESSIONAL PRACTICE; SYSTOLIC BLOOD PRESSURE; ACCURACY; CLINICAL PRACTICE; GENERAL PRACTICE; OUTCOME ASSESSMENT; STATISTICAL ANALYSIS;

ADULT; AGE FACTORS; AGED; AGED, 80 AND OVER; BLOOD PRESSURE DETERMINATION; BLOOD PRESSURE MONITORS; COHORT STUDIES; DIABETES MELLITUS, TYPE 2; FAMILY PRACTICE; FEMALE; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; PHYSICIAN'S PRACTICE PATTERNS; PROBABILITY; SENSITIVITY AND SPECIFICITY; SEX FACTORS;

EID: 31744451439     PISSN: 02632136     EISSN: None     Source Type: Journal    
DOI: 10.1093/fampra/cmi096     Document Type: Article

References (41)

1. Campbell NR, Myers MG, McKay DW. Is usual measurement of blood pressure meaningful? Blood Press Monit 1999; 4: 71-76.
2. O'Brien E, Asmar R, Beilin L et al. European Society of Hypertension recommendations for conventional, ambulatory and home blood pressure measurement. J Hypertens 2003; 21: 821-848.
3. Beevers G, Lip GY, O'Brien E. Blood pressure measurement. Part I. Sphygmomanometry: Factors common in all techniques. BMJ 2001; 322: 981-985.
4. McVicker JT. Blood pressure measurement does anyone do it right?: An assessment of the reliability of equipment in use and the measurement techniques of clinicians. J Fam Plann Reprod Health Care 2001; 27: 163-164.
5. McKay DW, Campbell NR, Parab LS, Chockalingam A, Fodor JG. Clinical assessment of blood pressure. J Hum Hypertens 1990; 4: 639-645.
6. Chobanian AV, Bakris GL, Black HR et al. Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003; 42: 1206-1252.
7. Ramsay L, Williams B, Johnston G et al. Guidelines for management of hypertension: Report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569-592.
8. Walma EP, Thomas S, Prins A, Grundmeyer HGLM, Van der Laan JR, Wiersma TJ. NHG-Standaard Hypertensie (derde herziening). (transl: NHG [Dutch General practitioners Society] guidelines for hypertension [3rd revision]). Huisarts Wet 2003; 46: 434-448.
9. Perloff D, Grim C, Flack J et al. Human blood pressure determination by sphygmomanometry. Circulation 1993; 88: 2460-2470.
10. Techniques of blood pressure measurement. In: CBO guideline High Blood Pressure. Alphen aan den Rijn: Van Zuiden Communications BV; 2000, 37-38.
11. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macro vascular and micro vascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
12. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macro vascular and micro vascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
13. Rutten GEHM, Verhoeven S, Heine RJ et al. NHG-Standaard Diabetes Mellitus Type 2 (eerste herziening). (NHG Practice Guideline Diabetes Mellitus Type 2 (first revision)). Huisarts Wet 1999; 42: 67-84.
14. Tholl U, Anlauf M, Lichtblau U, Dammer R. A clinical evaluation of the Omron R5-I (HEM-630) wrist blood pressure monitor and the Omron M5-I (HEM-757) upper arm blood pressure monitor, based on auscultation according to 'g″utesiegelprotocol'. Germany: Academic Hospital G″ottingen University, Bremerhaven Hochscule. Unpublished Report 2003.
15. El Assaad MA, Topouchian JA, Asmar RG. Evaluation of two devices for self-measurement of blood pressure according to the international protocol: The Omron M5-I and the Omron 705IT. Blood Press Monit 2003; 8: 127-133.
16. El Assaad M, Topouchian J, Le Dudal K, Labaki G, Asmar R. Validation of the Omron® M5-I blood pressure device according to the international validation protocol. J Hypertens 2003; 21(Suppl. 4): S23.
17. Bland JM, Altman DG. Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 1986; 1: 307-310.
18. Godley PJ, Maue SK, Farrelly EW, Frech F. The need for improved medical management of patients with concomitant hypertension and type 2 diabetes mellitus. Am J Manag Care 2005; 11: 206-210.
19. Sequeira RP, Al Khaja KA, Damanhori AH. Evaluating the treatment of hypertension in diabetes mellitus: A need for better control? J Eval Clin Pract 2004; 10: 107-116.
20. Berlowitz DR, Ash AS, Hickey EC, Glickman M, Friedman R, Kader B. Hypertension management in patients with diabetes: The need for more aggressive therapy. Diabetes Care 2003; 26: 355-359.
21. Schaars CF, Denig P, Kasje WN, Stewart RE, Wolffenbuttel BH, Haaijer-Ruskamp FM. Physician, organizational, and patient factors associated with suboptimal blood pressure management in type 2 diabetic patients in primary care. Diabetes Care 2004; 27: 123-128.
22. UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 1998; 317: 703-713.
23. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713-720.
24. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid- Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). JAMA 2002; 288: 2981-2997.
25. Davis BR, Cutler JA, Gordon DJ et al. Rationale and design for the antihypertensive and lipid lowering treatment to prevent heart attack trial (ALLHAT). ALLHAT Research Group. Am J Hypertens 1996; 9: 342-360.
26. Dahlof B, Devereux R, de Faire U et al. The Losartan Intervention For Endpoint reduction (LIFE) in hypertension study: Rationale, design, and methods. The LIFE Study Group. Am J Hypertens 1997; 10: 705-713.
27. Dahlof B, Devereux RB, Julius S et al. Characteristics of 9194 patients with left ventricular hypertrophy: The LIFE study. Losartan Intervention for endpoint reduction in hypertension. Hypertension 1998; 32: 989-997.
28. Dahlof B, Devereux RB, Kjeldsen SE et al. Cardiovascular morbidity and mortality in the Losartan intervention for endpoint reduction in hypertension study (LIFE): A randomised trial against atenolol. Lancet 2002; 359: 995-1003.
29. Hansson L, Zanchetti A, Carruthers SG et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: Principal results of the hypertension optimal treatment (HOT) randomised trial. HOT Study Group. Lancet 1998; 351: 1755-1762.
30. Keane WF, Brenner BM, de Zeeuw D et al. The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: The RENAAL study. Kidney Int 2003; 63: 1499-1507.
31. Brenner BM, Cooper ME, de Zeeuw D et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861-869.
32. Wing LM, Reid CM, Ryan P et al. Second Australian National Blood Pressure Study (ANBP2). Australian Comparative Outcome Trial of ACE inhibitor- and diuretic-based treatment of hypertension in the elderly. Management Committee on behalf of the High Blood Pressure Research Council of Australia. Clin Exp Hypertens 1997; 19: 779-791.
33. Wing LM, Reid CM, Ryan P et al. A comparison of outcomes with angiotensin-converting enzyme inhibitors and diuretics for hypertension in the elderly. N Engl J Med 2003; 348: 583-592.
34. The HOPE study investigators. The HOPE (Heart Outcomes Prevention Evaluation) Study: The design of a large, simple randomized trial of an angiotensin-converting enzyme inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 1996; 12: 127-137.
35. Yusuf S, Sleight P, Pogue J, Bosch J, Davies R, Dagenais G. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145-153.
36. Parving HH, Lehnert H, Brochner-Mortensen J, Gomis R, Andersen S, Arner P; Irbesartan in Patients with Type 2 Diabetes and Microalbuminuria Study Group. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001; 345: 870-878.
37. Forette F, Seux ML, Staessen JA et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet 1998; 352: 1347-1351.
38. Forette F, Seux ML, Staessen JA et al. The prevention of dementia with antihypertensive treatment: New evidence from the systolic hypertension in Europe (Syst-Eur) study. Arch Intern Med 2002; 162: 2046-2052.
39. Staessen JA, Fagard R, Thijs L et al. Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The systolic hypertension in Europe (Syst-Eur) trial investigators. Lancet 1997; 350: 757-764.
40. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic hypertension in the elderly program (SHEP). JAMA 1991; 265: 3255-3264.
41. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001; 358: 1033-1041.